European Semester Spring Package: Recommendations for a coordinated response to the coronavirus pandemic
-
-
EAN signed a Memorandum of Understanding with EPNS – European Paediatric Neurology Society joining forces to promote optimal cooperation in Europe between both societies. -
News from EAN member societiesOther NewsBMA – Joining Forces to strengthen European Health Research
BioMed Alliance Board Members publish an article outlining the need for cooperation. -
Alzheimer Europe’s 30th Annual Conference #30AEC, which was planned to take place in Bucharest, will now be a virtual conference, under the banner “Dementia in a changing world” -
EAN Congress newsOther NewsMake sure to participate in the joint congress programme developed in cooperation with EFAS & EAN
The autonomic nervous system (ANS) is in some ways distinct from other parts of the nervous system: ANS function cannot be easily measured, only some ANS parts are accessible to imaging. Moreover, working in the field of ANS requires a multidisciplinary approach to clinical problems and often involves other specialities such as cardiology, gastroenterology, dermatology, and urology. -
The Scientific
Panel on Movement Disorders Management Group invites you to join us for the
excellent Movement Disorders program at the EAN Virtual
Congress. The program has been prepared in collaboration between the
EAN and the International Parkinson and Movement Disorder… Continue Reading -
EAN NewsCOVID-19Education cornerOther NewsReflections of a medical student on the consequences and measures implemented at Grenoble-Alpes Medical School in the context of the COVID-19 pandemic
The arrival of the COVID-19 pandemic in my French region and also in Grenoble has radically changed how teaching classes have been organised in our Grenoble Alpes University Medical School. To better explain these changes, I need to illustrate how… Continue Reading -
Giovanni Di Liberto, MD-PhD Chair, RRFS – Residents and Research Fellows Section of the EAN Dr. Thomas Jenkins, Chair of the EAN e-Communication Committee interviews: Dear Dr. Di Liberto, You recently took over the leadership of the RRFS EAN section.… Continue Reading -
Neurological disorders are mostly chronic, long-term conditions. Those affected may be at increased risk from Covid-19. However, as this strain of the coronavirus is new, the knowledge on how this will affect people with neurological disorders is still limited. Based… Continue Reading
-
New gene therapy to treat spinal muscular atrophy On March 27, European Medicines Agency (EMA) recommended granting a conditional marketing authorisation in the European Union for the gene therapy Zolgensma (onasemnogene abeparvovec) to treat babies and young children with spinal… Continue Reading -
EMA has published its Regulatory Science Strategy to 2025 today. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines. It comes in response to the dramatic acceleration of the… Continue Reading
-
News from EAN member societiesOther NewsUncategorized
BioMed Alliance Task Force “Regulatory Affairs and Medical Devices”
Postponement of the application of the Medical Devices Regulation The European Commission adopted a proposal to postpone the application date of the Medical Devices regulation by one year, to 26 May 2021. The postponement is supposed to give authorities, manufacturers… Continue Reading -
Our country was relatively proactive in the containment measures it took, which meant that there was not a drastic and calamitous increase in the number of people infected and, necessarily, in the number of deaths caused by the virus. -
The EANcore COVID-19 inatitive has launched a survey on neurological symptoms in COVID-19 patients. -
News in generalCOVID-19EMA provides recommendations on compassionate use of remdesivir for COVID-19
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union.